We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3037:TWSEUnimicron Technology Corp. Analysis

Data as of 2026-06-11 - not real-time

NT$854.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Unimicron (3037.TW) is trading at TWD 854, well above its DCF‑derived fair value of roughly TWD 279, indicating a substantial premium. The stock sits above its 20‑day (≈TWD 947) and 50‑day (≈TWD 817) simple moving averages, with a bullish trend direction, yet the MACD shows a bearish signal and the RSI hovers near the neutral 45 mark, suggesting mixed short‑term momentum. Volume has been decreasing, and the 30‑day volatility is high at over 80%, reflecting a rattling market environment. Fundamentally, revenue grew 24.5% YoY and forward EPS is projected to surge, but margins remain thin, debt is sizable (debt‑to‑equity ≈ 50), and the trailing PE of ~196 dwarfs the industry average, flagging potential overvaluation.
The dividend yield is modest (0.23%) with a comfortable payout ratio (~34%), supporting dividend sustainability, while the company benefits from secular demand for advanced PCBs tied to AI and electronics growth. Investors should weigh the premium valuation and elevated risk against strong earnings upside and sector tailwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term support but MACD bearish divergence
  • Neutral RSI indicating limited upside momentum
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust revenue growth (24% YoY) and strong forward EPS outlook
  • Upside potential of ~10% versus DCF fair value
  • Sector tailwinds from AI‑driven PCB demand

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Secular growth in electronic components offset by high debt load
  • Persistent valuation premium relative to fair value
  • Sustainable dividend with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth24.50%
Profit Margin7.79%
P/E Ratio195.9
ROE11.00%
ROA2.03%
Debt/Equity49.69
P/B Ratio12.0
Op. Cash FlowNT$17.8B
Free Cash FlowNT$-336875136
Industry P/E36.5

Technical Analysis

TrendBullish
RSI44.6
SupportNT$776.00
ResistanceNT$1,130.00
MA 20NT$946.75
MA 50NT$816.60
MA 200NT$390.05
MACDBearish
VolumeDecreasing
Fear & Greed Index86.71

Valuation

Fair ValueNT$278.67
Target PriceNT$942.59
Upside/Downside10.37%
GradeOvervalued
TypeGrowth
Dividend Yield0.23%

Risk Assessment

Beta1.29
Volatility83.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.